Ignite Creation Date:
2024-05-06 @ 2:13 AM
Last Modification Date:
2024-10-26 @ 11:15 AM
Study NCT ID:
NCT01998126
Status:
COMPLETED
Last Update Posted:
2018-04-02
First Post:
2013-07-11
Brief Title:
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
Sponsor:
University of Utah
Organization:
University of Utah
Study Overview
Official Title:
Evaluation of Combination Checkpoint Inhibitor Plus Targeted Inhibitor Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer Phase Ib With Expansion Cohorts
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goals of the overall study are to evaluate a recommended phase 2 dose and the short and long term toxicities of the combinations This is a modified phase I trial of immune checkpoint inhibitors in combination with mutation - specific targeted therapy crizotinib or erlotinib at conventional doses stratified for presence of ALK Anaplastic lymphoma kinase or EGFR epidermal growth factor receptor mutation
The goals of the overall study are to evaluate a recommended phase 2 dose and the short and long term toxicities of the combinations
The goals of the overall study are to evaluate a recommended phase 2 dose and the short and long term toxicities of the combinations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None